in hospital treatment and heterogeneity in physicians' adherence to hospital choices. The spillover effects create cost …

Physicians' relationships with the pharmaceutical industry have recently come under public scrutiny, particularly in … indicate that both the number and the dollar- value of marketing visits increase physicians' patented opioid claims …

in hospital treatment and heterogeneity in the physicians' adherence to hospital choices. Our results suggest that …

pharmaceuticals. I examine micro-panel data from Japan, where physicians can legally make profits by prescribing and dispensing drugs …. The results indicate that physicians often fail to internalize patient costs, explaining why cheaper generics are …

manufacturers and physicians are uncertain about drug qualities. Our model assumes (i) a representative opinion leader is … (ii) manufacturers use detailing as a means to build/maintain the measure of physicians who are informed of the current … detailing to the current information sets and the measures of well-informed physicians. To illustrate the empirical implications …

prescription products to physicians at a less expensive way than traditional detailing. In the proposed promotion response model …

Physicians’ generic pharmaceutical adoption involves not only patients’ and insurance payers’ cost, but also their own … interests. This study examines this double agency problem for physicians by using Taiwanese data because two of its … institutional features: First, patients and physicians in a universal health care system did not self-select their insurance plans …

established in the community for it to be prescribed more heavily by specialists and target physicians in solo practice and newer … physicians to speed up the adoption process. Furthermore, for newer drugs traditional forms of detailing via a live sales rep are …